CA3079389A1 - Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis - Google Patents
Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis Download PDFInfo
- Publication number
- CA3079389A1 CA3079389A1 CA3079389A CA3079389A CA3079389A1 CA 3079389 A1 CA3079389 A1 CA 3079389A1 CA 3079389 A CA3079389 A CA 3079389A CA 3079389 A CA3079389 A CA 3079389A CA 3079389 A1 CA3079389 A1 CA 3079389A1
- Authority
- CA
- Canada
- Prior art keywords
- data
- evidence
- variant
- aspects
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
- G06F18/211—Selection of the most significant subset of features
- G06F18/2113—Selection of the most significant subset of features by ranking or filtering the set of features, e.g. using a measure of variance or of feature cross-correlation
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
- G06F18/20—Analysing
- G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
- G06F18/217—Validation; Performance evaluation; Active pattern learning techniques
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/10—Ontologies; Annotations
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/01—Protocols
- H04L67/10—Protocols in which an application is distributed across nodes in the network
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
- H04L9/06—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for block-wise or stream coding, e.g. DES systems or RC4; Hash functions; Pseudorandom sequence generators
- H04L9/0618—Block ciphers, i.e. encrypting groups of characters of a plain text message using fixed encryption transformation
- H04L9/0637—Modes of operation, e.g. cipher block chaining [CBC], electronic codebook [ECB] or Galois/counter mode [GCM]
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
- H04L9/06—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for block-wise or stream coding, e.g. DES systems or RC4; Hash functions; Pseudorandom sequence generators
- H04L9/0643—Hash functions, e.g. MD5, SHA, HMAC or f9 MAC
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
- H04L9/50—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols using hash chains, e.g. blockchains or hash trees
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Data Mining & Analysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Analytical Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Genetics & Genomics (AREA)
- Software Systems (AREA)
- Computer Security & Cryptography (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Power Engineering (AREA)
- Mathematical Physics (AREA)
- Computing Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573458P | 2017-10-17 | 2017-10-17 | |
| US62/573,458 | 2017-10-17 | ||
| PCT/US2018/056304 WO2019079464A1 (en) | 2017-10-17 | 2018-10-17 | PLATFORM OF MOLECULAR EVIDENCE FOR CONTINUOUS AND VERIFY OPTIMIZATION OF INTERPRETATION OF VARIANTS IN TESTS AND GENETIC ANALYZES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3079389A1 true CA3079389A1 (en) | 2019-04-25 |
Family
ID=66174641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3079389A Pending CA3079389A1 (en) | 2017-10-17 | 2018-10-17 | Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11462299B2 (https=) |
| EP (1) | EP3701534B1 (https=) |
| JP (1) | JP7258871B2 (https=) |
| CN (1) | CN112074909B (https=) |
| AU (1) | AU2018350975B2 (https=) |
| BR (1) | BR112020007449A2 (https=) |
| CA (1) | CA3079389A1 (https=) |
| IL (1) | IL274001A (https=) |
| MX (1) | MX2020003709A (https=) |
| WO (1) | WO2019079464A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7258871B2 (ja) | 2017-10-17 | 2023-04-17 | インビタエ コーポレイション | 遺伝子及びゲノムの検査並びに分析におけるバリアント解釈の、監査可能な継続的な最適化のための分子エビデンスプラットフォーム |
| US10959277B2 (en) * | 2019-04-01 | 2021-03-23 | T-Mobile Usa, Inc. | Mobile device network performance restoration and improvement |
| US10764062B2 (en) * | 2019-06-03 | 2020-09-01 | Alibaba Group Holding Limited | Blockchain ledger compression |
| CN110602162B (zh) * | 2019-08-06 | 2022-11-01 | 苏州龙信信息科技有限公司 | 终端取证方法、装置、设备和存储介质 |
| CN110957006B (zh) * | 2019-12-14 | 2023-08-11 | 杭州联川基因诊断技术有限公司 | 一种brca1/2基因变异的解读方法 |
| CN112489812B (zh) * | 2020-11-30 | 2021-07-06 | 北京华彬立成科技有限公司 | 药物开发分析方法、装置、电子设备和存储介质 |
| WO2022198625A1 (zh) * | 2021-03-26 | 2022-09-29 | 深圳华大基因股份有限公司 | 变异文献解读知识库的构建方法、解读方法及电子设备 |
| US20230351337A1 (en) * | 2022-04-29 | 2023-11-02 | Bank Of America Corporation | Generating and securing digital checks using distributed ledger and embedded chip methods |
| US12211039B2 (en) * | 2022-09-20 | 2025-01-28 | Veiovia Limited | Externally validated proof of work for appending a block record to a blockchain with a data broker server |
| US11652650B1 (en) * | 2022-09-20 | 2023-05-16 | Veiovia Limited | Externally validated proof of work for appending a block record to a blockchain with a commitment database server |
| US12216661B2 (en) | 2022-09-20 | 2025-02-04 | Veiovia Ltd. | Externally validated proof of work for appending a block record to a blockchain with a mining node |
| WO2025115360A1 (ja) * | 2023-11-30 | 2025-06-05 | 富士フイルム株式会社 | 木構造生成方法、情報処理装置、情報処理システム、及び木構造生成プログラム |
| CN119719955B (zh) * | 2024-12-17 | 2025-09-05 | 四川大学华西医院 | 一种基于贝叶斯模型的证据优化方法、装置、计算机设备及存储介质 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972693A (en) | 1995-10-24 | 1999-10-26 | Curagen Corporation | Apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing |
| US6949692B2 (en) | 1996-11-18 | 2005-09-27 | Wisconsin Alumni Research Foundation | Method for identifying mutants and molecules |
| US5780236A (en) | 1996-11-18 | 1998-07-14 | Wisconsin Alumni Research Foundation | Method for identifying mutants and molecules |
| US7135286B2 (en) | 2002-03-26 | 2006-11-14 | Perlegen Sciences, Inc. | Pharmaceutical and diagnostic business systems and methods |
| US20060223058A1 (en) * | 2005-04-01 | 2006-10-05 | Perlegen Sciences, Inc. | In vitro association studies |
| US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
| EP2064345B1 (en) | 2006-09-11 | 2013-03-13 | Celera Corporation | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof |
| KR101325736B1 (ko) * | 2010-10-27 | 2013-11-08 | 삼성에스디에스 주식회사 | 바이오 마커 추출 장치 및 방법 |
| WO2012066582A1 (en) | 2010-11-18 | 2012-05-24 | Decode Genetics Ehf | Genetic risk factors of sick sinus syndrome |
| US8744982B2 (en) * | 2011-05-12 | 2014-06-03 | University Of Utah Research Foundation | Gene-specific prediction |
| US8718950B2 (en) * | 2011-07-08 | 2014-05-06 | The Medical College Of Wisconsin, Inc. | Methods and apparatus for identification of disease associated mutations |
| US9773091B2 (en) * | 2011-10-31 | 2017-09-26 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
| US9235686B2 (en) | 2012-01-06 | 2016-01-12 | Molecular Health Gmbh | Systems and methods for using adverse event data to predict potential side effects |
| US20140089009A1 (en) * | 2012-09-27 | 2014-03-27 | Wobblebase, Inc. | Method for Personal Genome Data Management |
| US9792405B2 (en) | 2013-01-17 | 2017-10-17 | Edico Genome, Corp. | Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform |
| EP4414988A3 (en) * | 2013-01-31 | 2024-11-06 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules using models of multiplicative form |
| WO2014149972A1 (en) * | 2013-03-15 | 2014-09-25 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
| US20160048633A1 (en) * | 2013-03-15 | 2016-02-18 | Cypher Genomics, Inc. | Systems and methods for genomic variant annotation |
| WO2014151764A2 (en) * | 2013-03-15 | 2014-09-25 | Veracyte, Inc. | Methods and compositions for classification of samples |
| JP6566484B2 (ja) * | 2013-06-14 | 2019-08-28 | キージーン ナムローゼ フェンノートシャップ | 表現形質改善のための制御された戦略 |
| US20150025861A1 (en) * | 2013-07-17 | 2015-01-22 | The Johns Hopkins University | Genetic screening computing systems and methods |
| WO2015027085A1 (en) * | 2013-08-22 | 2015-02-26 | Genomoncology, Llc | Computer-based systems and methods for analyzing genomes based on discrete data structures corresponding to genetic variants therein |
| US20160314245A1 (en) | 2014-06-17 | 2016-10-27 | Genepeeks, Inc. | Device, system and method for assessing risk of variant-specific gene dysfunction |
| JP2017527050A (ja) * | 2014-06-30 | 2017-09-14 | キアゲン レッドウッド シティ, インコーポレイテッドQiagen Redwood City, Inc. | 配列に基づいた遺伝子検査の解釈および報告のための方法およびシステム |
| KR102068451B1 (ko) | 2014-09-03 | 2020-01-20 | 난트헬쓰, 인코포레이티드 | 합성 게놈 변형-기반의 보안 트랜잭션 디바이스들, 시스템들 및 방법들 |
| CA2980327A1 (en) * | 2015-03-26 | 2016-09-29 | Quest Diagnostics Investments Incorporated | Alignment and variant sequencing analysis pipeline |
| EP3286677A4 (en) * | 2015-04-22 | 2019-07-24 | Genepeeks, Inc. | DEVICE, SYSTEM AND METHOD FOR ASSESSING THE RISK OF VARIATION SPECIFIC GENDYS FUNCTION |
| US10185803B2 (en) * | 2015-06-15 | 2019-01-22 | Deep Genomics Incorporated | Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network |
| CA3018705A1 (en) | 2016-03-21 | 2017-09-28 | Human Longevity, Inc. | Genomic, metabolomic, and microbiomic search engine |
| JP7258871B2 (ja) | 2017-10-17 | 2023-04-17 | インビタエ コーポレイション | 遺伝子及びゲノムの検査並びに分析におけるバリアント解釈の、監査可能な継続的な最適化のための分子エビデンスプラットフォーム |
| US10978196B2 (en) * | 2018-10-17 | 2021-04-13 | Tempus Labs, Inc. | Data-based mental disorder research and treatment systems and methods |
| US20200121715A1 (en) | 2018-10-20 | 2020-04-23 | MC Technology Holdings, LLC | Composition comprising aqueous medium with reduced size water clusters to improve bioavailability of the aqueous medium and methods for making and using the compositions |
-
2018
- 2018-10-17 JP JP2020522707A patent/JP7258871B2/ja active Active
- 2018-10-17 MX MX2020003709A patent/MX2020003709A/es unknown
- 2018-10-17 WO PCT/US2018/056304 patent/WO2019079464A1/en not_active Ceased
- 2018-10-17 BR BR112020007449-7A patent/BR112020007449A2/pt not_active Application Discontinuation
- 2018-10-17 US US16/162,889 patent/US11462299B2/en active Active
- 2018-10-17 AU AU2018350975A patent/AU2018350975B2/en active Active
- 2018-10-17 CA CA3079389A patent/CA3079389A1/en active Pending
- 2018-10-17 US US16/756,802 patent/US20200251179A1/en not_active Abandoned
- 2018-10-17 EP EP18868620.8A patent/EP3701534B1/en active Active
- 2018-10-17 CN CN201880081247.7A patent/CN112074909B/zh active Active
-
2020
- 2020-04-16 IL IL274001A patent/IL274001A/en unknown
-
2022
- 2022-09-16 US US17/946,942 patent/US11798651B2/en active Active
-
2023
- 2023-09-14 US US18/368,375 patent/US12136472B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019079464A1 (en) | 2019-04-25 |
| US11462299B2 (en) | 2022-10-04 |
| US12136472B2 (en) | 2024-11-05 |
| EP3701534B1 (en) | 2024-04-10 |
| AU2018350975B2 (en) | 2023-11-23 |
| MX2020003709A (es) | 2020-07-22 |
| AU2018350975A1 (en) | 2020-05-07 |
| CN112074909A (zh) | 2020-12-11 |
| EP3701534C0 (en) | 2024-04-10 |
| JP2020537795A (ja) | 2020-12-24 |
| BR112020007449A2 (pt) | 2020-10-20 |
| US20200251179A1 (en) | 2020-08-06 |
| CN112074909B (zh) | 2024-03-19 |
| IL274001A (en) | 2020-05-31 |
| US20240006021A1 (en) | 2024-01-04 |
| US20190189246A1 (en) | 2019-06-20 |
| JP7258871B2 (ja) | 2023-04-17 |
| EP3701534A4 (en) | 2021-08-04 |
| US11798651B2 (en) | 2023-10-24 |
| EP3701534A1 (en) | 2020-09-02 |
| US20230117854A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12136472B2 (en) | Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis | |
| US10867702B2 (en) | Individual and cohort pharmacological phenotype prediction platform | |
| Smith et al. | Classification of genes: standardized clinical validity assessment of gene–disease associations aids diagnostic exome analysis and reclassifications | |
| Register-Brown et al. | Reliability and validity of methods for measuring the duration of untreated psychosis: a quantitative review and meta-analysis | |
| EP4260340A1 (en) | Predicting fractional flow reserve from electrocardiograms and patient records | |
| JP2010522537A (ja) | 遺伝子分析系および方法 | |
| Bascom et al. | Heritable disorders of connective tissue: Description of a data repository and initial cohort characterization | |
| Zhou et al. | A phenome-wide scan reveals convergence of common and rare variant associations | |
| Yang et al. | Genomic and multi-tissue proteomic integration for understanding the biology of disease and other complex traits | |
| Leon‐Quintero et al. | Modified rules for classification of variants associated with disorders of somatic mosaicism | |
| Feng et al. | Psychiatric manifestations of rare variation in medically actionable genes: a PheWAS approach | |
| Chakraborty et al. | A quantitative trait GWAS on lens thickness identifies novel risk loci on PTPRM in the narrow angle individuals susceptible to PACG | |
| Poku et al. | Developing novel prognostic biomarkers for multivariate fracture risk prediction algorithms | |
| Kang et al. | Genome-wide association study of treatment resistant depression highlights shared biology with metabolic traits | |
| Kunorozva et al. | From Normal Variation in Sleep to Clinical Sleep Disorders: Genetic Insights from Over One Million Individuals | |
| Pott et al. | Mendelian Randomization with longitudinal exposure data: simulation study and real data application | |
| Li et al. | Integration of public DNA methylation and expression networks via eQTMs improves prediction of functional gene–gene associations | |
| Huerta | Human Phenotype Ontology-driven comparison of whole exome sequencing findings in a tertiary center | |
| WO2024129783A1 (en) | Systems and methods for patient-specific treatment recommendation optimized with multistage machine learning | |
| Zheng et al. | Polygenic score for C-reactive protein is linked to faster cortical thinning and psychopathology risk in adolescents | |
| Gehlawat et al. | Technology-enabled precision medicine in neurodevelopmental disorders | |
| Ruderfer | Genome-ide association stud of treatment-resistant depression: shared biolog ith metabolic traits | |
| Jr et al. | Genome-wide association study of treatment resistant depression highlights shared biology with metabolic traits | |
| Dattani | downloaded from the King’s Research Portal at https://kclpure. kcl. ac. uk/portal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220930 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240815 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241021 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250408 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250408 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250605 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250728 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250728 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250728 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250731 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250818 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250825 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250825 |